Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Horizant for RLS Augmentation
NCT02642315Completed
- Sponsor
- University of Missouri
- Start
- Jan 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gabapentin enacarbil in restless legs syndrome (RLS), sponsored by University of Missouri. Primary endpoint: Change in Augmentation Severity From Day 0 to Day 90. Started Jan 2016; status: completed.
02
Drugs
gabapentin enacarbil
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT02642315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02642315.